UCB SA
UCB: XBRU (BEL)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| %d^ | LOCK|>W | LOCK|j@l?Bdp |
UCB: Positive Long-Term Data Reinforces Confidence in Key Growth Drivers
During the second quarter, UCB presented additional long-term data for Bimzelx, published further evidence supporting recently launched rare-disease therapy Kygevvi, and released long-term data for Rystiggo and Zilbrysq. UCB reports half-yearly, with financial results due at the end of July.
